Floatz logo

Pelacarsen

Cardiovascular Disease and Lipoprotein(a)

Novartis PharmaceuticalsPhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

59 Active assets in the Cardiovascular Disease and Lipoprotein(a) cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
AstraZeneca
Phase 4BBB
Liraglutide
University of Sao Paulo General Hospital
Phase 4BBB
Lipitor
Duke University
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
SIMVASTATIN
McMaster University
Phase 4BBB

View all 50 →

Same molecule, other indications

Pelacarsen is also rated in:

acute coronary syndromeDormant
D
Indicative ·
30 / 100
View asset →
hyperlipoproteinemiaDormant
D
Indicative ·
30 / 100
View asset →
inflammatory diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →